Observational studyCancer reports (Hoboken, N.J.)2026
Ribociclib and Palbociclib Are Safe and Effective for Treating Metastatic Breast Cancer: A Retrospective Study.
Observational study in Cancer reports (Hoboken, N.J.), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
backgroundCyclin-dependent kinase (CDK) 4/6 inhibitors are standard for treating hormone receptor-positive metastatic breast cancer when combined with endocrine therapy. However, comparisons of first-line treatments are scarce.
aimsIn this retrospective study, we aimed to determine the effects and safety of ribociclib and palbociclib as first-line treatments for metastatic hormone receptor-positive breast cancer in real-world settings at two tertiary medical centers. METHODS AND
resultsThis retrospective observational study, conducted in two tertiary medical centers, included patients receiving palbociclib or ribociclib in combination with endocrine therapy. Treatment responses were assessed by imaging studies according to RECIST 1.1 criteria. The primary endpoint was 24-month progression-free survival (PFS). Safety outcomes were also recorded and compared between the treatment groups. The median follow-up times for the ribociclib and palbociclib groups were 19.7 and 24.6 months, respectively. The 24-month PFS rates were comparable between the ribociclib and palbociclib cohorts (55.4% vs. 55.2%, respectively; hazard ratio [HR] = 1.110, 95% confidence interval [CI]: 0.605-2.035; p = 0.736), but the objective response rate was significantly higher in the palbociclib group than in the ribociclib group (43.2% vs. 30.2%, p = 0.035). A high rate of dose reduction was observed in both cohorts due to treatment-related toxicities (41.2% in the palbociclib group vs. 47.2% in the ribociclib group). The adverse effect profiles were comparable, although the incidence of grade 1 fatigue was slightly higher in the ribociclib group than in the palbociclib group (p = 0.043).
conclusionIn Taiwanese real-world practice, ribociclib and palbociclib demonstrated comparable 24-month efficacy. Our findings show that dose reductions do not compromise targeted treatment efficacy, supporting proactive toxicity-guided dose to optimize patient tolerability without sacrificing oncological outcomes in Asian populations.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.